FAQs
1. Does lifestyle affect when symptoms start?
While the number of CAG repeats is the primary factor, research suggests lifestyle factors such as exercise, mental stimulation, and diet may modestly influence how quickly symptoms appear or progress, though they cannot prevent the disease.
2. Is Huntington’s disease contagious?
No. Huntington’s disease is not an infection—it is a purely genetic condition. It cannot be “caught” or transmitted through contact, blood, or sexual activity.
3. Can someone with HD have healthy children?
Yes. Options such as preimplantation genetic testing with in-vitro fertilization (IVF) allow families to have children who do not inherit the mutation. Some also choose prenatal testing during pregnancy, though this comes with ethical and emotional complexities.
Reference
1. Bates, G. P., Dorsey, R., Gusella, J. F., et al. (2015). Huntington disease. Nature reviews Disease primers, 1(1), 1-21.
2. Ridley, R. M., Frith, C. D., Crow, T. J., et al. (1988). Anticipation in Huntington’s disease is inherited through the male line but may originate in the female. Journal of medical genetics, 25(9), 589-595.
3. Csehi, R., Molnar, V., Fedor, M., et al. (2023). The improvement of motor symptoms in Huntington’s disease during cariprazine treatment. Orphanet Journal of Rare Diseases, 18(1), 375.
4. Moumné, L., Betuing, S., & Caboche, J. (2013). Multiple aspects of gene dysregulation in Huntington’s disease. Frontiers in neurology, 4, 127.
5. Harding, R. J., & Tong, Y. F. (2018). Proteostasis in Huntington’s disease: disease mechanisms and therapeutic opportunities. Acta Pharmacologica Sinica, 39(5), 754.
6. Crotti, A., & Glass, C. K. (2015). The choreography of neuroinflammation in Huntington’s disease. Trends in immunology, 36(6), 364-373.
7. Schneider, S. A., & Bird, T. (2016). Huntington’s Disease, Huntington’s Disease Look‐Alikes, and Benign Hereditary Chorea: What’s New?. Movement disorders clinical practice, 3(4), 342-354.
8. Roos, R. A. (2010). Huntington’s disease: a clinical review. Orphanet journal of rare diseases, 5(1), 40.
9. Carlozzi, N. E., Boileau, N. R., Roberts, A., et al. (2021). Understanding speech and swallowing difficulties in individuals with Huntington disease: Validation of the HDQLIFE Speech Difficulties and Swallowing Difficulties Item Banks. Quality of Life Research, 30(1), 251-265.
10. Paulsen, J. S., Hoth, K. F., Nehl, C., et al. (2005). Critical periods of suicide risk in Huntington’s disease. American Journal of Psychiatry, 162(4), 725-731.
11. Losekoot, M., Van Belzen, M. J., Seneca, S., et al. (2013). EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease. European Journal of Human Genetics, 21(5), 480-486.
12. Scahill, R. I., Farag, M., Murphy, M. J., et al. (2025). Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington’s disease decades before clinical motor diagnosis. Nature medicine, 31(3), 807-818.
13. Leite, Â. M. T., Dinis, M. A. P., da Silva Pinto, S. M. L., et al. (2017). Long-term negative psychological impact of presymptomatic testing for Huntington Disease. Journal of Health, Medicine and Nursing, 34.
14. Kinnunen, K. M., Schwarz, A. J., Turner, E. C., et al. (2021). Volumetric MRI-based biomarkers in Huntington’s disease: an evidentiary review. Frontiers in Neurology, 12, 712555.
15. Feigin, A., Leenders, K. L., Moeller, J. R., et al. (2001). Metabolic network abnormalities in early Huntington’s disease: an [18F] FDG PET study. Journal of Nuclear Medicine, 42(11), 1591-1595.
16. Paulsen, J. S., Zimbelman, J. L., Hinton, S. C., et al. (2004). fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington’s disease. American Journal of Neuroradiology, 25(10), 1715-1721.
17. Claassen, D. O., Ayyagari, R., Garcia-Horton, V., et al. (2022). Real-world adherence to tetrabenazine or deutetrabenazine among patients with Huntington’s disease: a retrospective database analysis. Neurology and Therapy, 11(1), 435-448.
18. Videnovic, A. (2013). Treatment of huntington disease. Current treatment options in neurology, 15(4), 424-438.
19. Smalley, J. L., Breda, C., Mason, R. P., et al. (2016). Connectivity mapping uncovers small molecules that modulate neurodegeneration in Huntington’s disease models. Journal of Molecular Medicine, 94(2), 235-245.
20. Ogilvie, A. C., Carnahan, R. M., Chrischilles, E. A., et al. (2022). The effects of antidepressants on depressive symptoms in manifest Huntington’s disease. Journal of psychosomatic research, 162, 111023.
21. Scheuing, L., Chiu, C. T., Liao, H. M., et al. (2014). Preclinical and clinical investigations of mood stabilizers for Huntington’s disease: what have we learned?. International journal of biological sciences, 10(9), 1024.
22. Bilney, B., Morris, M. E., & Perry, A. (2003). Effectiveness of physiotherapy, occupational therapy, and speech pathology for people with Huntington’s disease: a systematic review. Neurorehabilitation and neural repair, 17(1), 12-24.
23. Gaba, A. (2025). Nutrition and Huntington’s Disease–A Review of Current Practice and Theory. Current Nutrition Reports, 14(1), 18.
24. Pascu, A. M., Ifteni, P., Teodorescu, A., et al. (2015). Delayed identification and diagnosis of Huntington’s disease due to psychiatric symptoms. International journal of mental health systems, 9(1), 33.
25. Lakra, P., Aditi, K., & Agrawal, N. (2019). Peripheral expression of mutant huntingtin is a critical determinant of weight loss and metabolic disturbances in Huntington’s disease. Scientific reports, 9(1), 10127.
26. Byrne, L. M., Rodrigues, F. B., Blennow, K., et al. (2017). Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. The Lancet Neurology, 16(8), 601-609.
27. Travessa, A. M., Rodrigues, F. B., Mestre, T. A., et al. (2017). Fifteen years of clinical trials in Huntington’s disease: A very low clinical drug development success rate. Journal of Huntington’s disease, 6(2), 157-163.
28. Yao, J. Y., Liu, T., Hu, X. R et al. (2024). An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington’s disease treatment. Biomedicine & Pharmacotherapy, 180, 117557.
29. Rook, M. E., & Southwell, A. L. (2022). Antisense oligonucleotide therapy: from design to the Huntington disease clinic. BioDrugs, 36(2), 105.
30. Sava, V., Fihurka, O., Khvorova, A., et al. (2020). Enriched chitosan nanoparticles loaded with siRNA are effective in lowering Huntington’s disease gene expression following intranasal administration. Nanomedicine: Nanotechnology, Biology and Medicine, 24, 102119.
31. Alkanli, S. S., Alkanli, N., Ay, A., et al. (2023). CRISPR/Cas9 mediated therapeutic approach in Huntington’s disease. Molecular Neurobiology, 60(3), 1486-1498.
32. Croce, K. R., & Yamamoto, A. (2018). A role for autophagy in Huntington’s disease. Neurobiology of disease, 122, 16.
33. Liang, X. S., Sun, Z. W., Thomas, A. M., et al. (2023). Mesenchymal Stem Cell Therapy for Huntington Disease: A Meta‐Analysis. Stem Cells International, 2023(1), 1109967.
34. Jung, Y., & Damoiseaux, J. S. (2024). The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer’s disease. Brain, 147(1), 12-25.
35. Parekh, N., Bhagat, A., Raj, B., et al. (2023). Artificial intelligence in diagnosis and management of Huntington’s disease. Beni-Suef University Journal of Basic and Applied Sciences, 12(1), 87.
36. Williams, J. K., Skirton, H., Paulsen, J. S., et al. (2009). The emotional experiences of family carers in Huntington disease. Journal of advanced nursing, 65(4), 789-798.
37. Skirton, H., Williams, J. K., Jackson Barnette, J., et al. (2010). Huntington disease: families’ experiences of healthcare services. Journal of advanced nursing, 66(3), 500-510.